07:11 AM EDT, 10/30/2024 (MT Newswires) -- Eli Lilly ( LLY ) reported Q3 non-GAAP earnings Wednesday of $1.18 per diluted share, up from $0.10 a year earlier.

Analysts polled by Capital IQ expected $1.47.

Revenue for the quarter ended Sept. 30 was $11.44 billion, compared with $9.50 billion a year earlier.

Analysts surveyed by Capital IQ expected $12.12 billion.

The drug manufacturer lowered its full-year 2024 non-GAAP earnings guidance to a range of $13.02 to $13.52 per share, from $16.10 to $16.60 previously. Analysts polled by Capital IQ expect $13.45.

Lilly narrowed its revenue outlook for the year to $45.4 billion to $46 billion, from $45.4 billion to $46.6 billion previously. Analysts surveyed by Capital IQ expect $46.22 billion.

Lilly shares fell more than 10% in recent premarket activity.

Price: 808.47, Change: -95.11, Percent Change: -10.53